Skip to main content
SpringerLink
Log in

Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases

  • Protocol
Anticoagulants, Antiplatelets, and Thrombolytics

Part of the book series: Methods In Molecular Medicine™ ((MIMM,volume 93))

  • 509 Accesses

Abstract

Despite the research and development efforts in newer anticoagulants, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) will continue to play a pivotal role in the management of thrombotic disorders. Although bleeding and heparin-induced thrombocytopenia (HIT) represent major side effects of this drug, it has remained the anticoagulant of choice for the prophylaxis and treatment of arterial and venous thrombotic disorders, surgical anticoagulation, and interventional usage. It is the understanding of the structure of heparin that led to the development of LMWHs, synthetic hepari-nomimetics, antithrombin (AT), and anti-Xa agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weitz, J. I. (1997) Low-molecular-weight heparin. N. Engl. J. Med. 337, 688–698.

    Article  PubMed  CAS  Google Scholar 

  2. Mousa, S. A. and Fareed, J. W. (2001) Advances in anticoagulant, antithrombotic and thrombolytic drugs. Exp. Opin. Invest. Drugs 10(1), 157–162.

    Article  CAS  Google Scholar 

  3. Fegan, C. D. (1998) Tinzaparin as an antithrombotic: an overview. Hosp. Med. 149, 1285–1288.

    Google Scholar 

  4. Aguilar, D. and Goldhaber, S. Z. (1999) Clinical uses of low molecular weight heparin. Chest 115(5), 1418–1423.

    Article  PubMed  CAS  Google Scholar 

  5. Linhardt, R. J. and Gunay, N. S. (1999) Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25(3), 5–16.

    PubMed  CAS  Google Scholar 

  6. Mousa, S. A. (2000) Comparative efficacy among different low molecular weight heparin (LMWHs) & drug interaction: implications in the management of vascular disorders. Thromb. Haemostasis 26(l)(Suppl. 1), 39–46. This study provides a comparative total anticoagulant efficacy among different LMWH showing dependency on the molecular weight and degree of sulfation.

    Article  CAS  Google Scholar 

  7. Hull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Towbridge, A. A., Elliott, C. G, et al. (1992) Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326, 975–982. This is a key double-blind clinical trial comparing the efficacy and safety of LMWH to UFH in-patients with VTE.

    Article  PubMed  CAS  Google Scholar 

  8. Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Bosson, J.-L., et al. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. 337, 663–669.

    Article  PubMed  CAS  Google Scholar 

  9. Hull, R. D., Raskob, G E., Pineo, G F., Rosenbloom, D., Evans, W., Mallory, T., et al. (1993) A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med. 329, 1370–1376.

    Article  PubMed  CAS  Google Scholar 

  10. Leizorovicz, A., Picolet, H., Peyrieux, J. C, Boissel, J. P., and the HBPM research group. (1991) Prevention of perioperative deep vein thrombosis in general surgery: a multicenter double blind study comparing two doses of logiparin and standard heparin. Br. J. Surg. 78, 412–416.

    Article  Google Scholar 

  11. Ryan, K. E., Lane, D. A., Flynn, A., Shepperd, J., Ireland, H. A., and Curtis, J. R. (1991) Dose finding study of a low molecular weight heparin, tinzaparin, in haemodialysis. Thromb. Haemostasis 66(3), 277–282.

    CAS  Google Scholar 

  12. Pedersen, P. C, Østergaard, P. B., Hedner, U., Bergqvist, D., and Mätzsch, T. (1991) Pharmacokinetics of low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb. Res. 61, 477–487.

    Article  PubMed  CAS  Google Scholar 

  13. Mätzsch, T., Bergqvist, D., Hedner, U., and Østergaard, P. B. (1987) Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb. Haemostasis 57(1), 97–101.

    Google Scholar 

  14. Mousa, S. A., Bozarth, J., Hainer, J., et al. (2001) Pharmacodynamic of tinzaparin following 175 IU/Kg SC administration in healthy volunteers on plasma TFPI. Thromb. Haemostasis P2299.

    Google Scholar 

  15. Emmanuele, R. M. and Fareed, J. (1987) The effect of molecular weight on the bioavailability of heparin. Thromb. Res. 48, 591–596.

    Article  Google Scholar 

  16. Brieger, D. and Dawes, J. (1997) Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb. Haemostasis 77(2), 317–322.

    CAS  Google Scholar 

  17. Mousa, S. A., Bozarth, J., Larnkjaer, A., and Johanson, K. (2000) Vascular effects of heparin molecular weight fractions and LMWH on the release of TFPI from human endothelial cells. Blood 16(11), 59, 3928.

    Google Scholar 

  18. Kaiser, B., Hoppensteadt, D., and Fareed, J. (2000) Tissue factor pathway inhibitor for cardiovascular disorders. Emerging Drugs 5(1), 73–87.

    Article  CAS  Google Scholar 

  19. Verstraete, M. (1990) Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40, 498–530.

    Article  PubMed  CAS  Google Scholar 

  20. Lindblad, B. (1988) Prophylaxis of postoperative thromboembolism with low dose heparin alone or in combination with dihydroergotamine. A review. Acta Chir. Scand. Suppl. 543, 31–42.

    CAS  Google Scholar 

  21. Hull, R., Delmore, T, Carter, C, Hirsh, J., Genton, E., Gent, M., et al. (1982) Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306, 189–194.

    Article  PubMed  CAS  Google Scholar 

  22. Hull, R. D., Raskob, G E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., et al. (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. 315, 1109–1114.

    Article  PubMed  CAS  Google Scholar 

  23. Cruickshank, M. K., Levine, M. N., Hirsh, J., Roberts, R., and Siguenza, M. (1991) A standard heparin nomogram for the management of heparin therapy [see comments]. Arch. Intern. Med. 151, 333–337.

    Article  PubMed  CAS  Google Scholar 

  24. Hull, R. D., Raskob, G. E., Rosenbloom, D., Lemaire, J., Pineo, G. F, Baylis, B., et al. (1992) Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Intern. Med. 152, 1589–1595.

    Article  PubMed  CAS  Google Scholar 

  25. Goldhaber, S. Z. (1996) Thrombolytic therapy for venous thromboembolism, in Disorders of Thrombosis (Hull, R. and Pineo, G. F., eds.), W.B. Saunders Co, pp. 321–328.

    Google Scholar 

  26. Gueret, P., Dubourg, O., Ferrier, A., Farcot, J. C, Rigaud, M., and Bourdarias, J. P. (1986) Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. J. Am. Coll. Cardiol. 8, 419–426.

    Article  PubMed  CAS  Google Scholar 

  27. Neri Serneri, G. G, Gensini, G. F, Poggesi, L., Trotta, F, Modesti, P. A., Boddi, M., et al. (1990) Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina (published erratum appears in Lancet 1990 Apr 7;335[8693]:868). Lancet 335, 615–618.

    Google Scholar 

  28. Bounameaux, H., Verhaeghe, R., and Verstraete, M. (1986) Thromboembolism and antithrombotic therapy in peripheral arterial disease. J. Am. Coll. Cardiol. 8, 98B–103B.

    Article  PubMed  CAS  Google Scholar 

  29. Matzsch, T., Bergqvist, D., Hedner, U., Nilsson, B., and Ostergaard, P. (1986) Heparin-induced osteoporosis in rats. Thromb. Haemostasis 56, 293–294.

    CAS  Google Scholar 

  30. Salzman, E. W., Rosenberg, R. D., Smith, M. H., Lindon, J. N., and Favreau, L. (1980) Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 65, 64–73.

    Article  PubMed  CAS  Google Scholar 

  31. Friedel, H. A. and Balfour, J. A. (1994) Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48, 638–660.

    Article  PubMed  CAS  Google Scholar 

  32. Padilla, A., Gray, E., Pepper, D. S., and Barrowcliffe, T. W. (1992) Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br. J. Haematol. 82, 406–413.

    Article  PubMed  CAS  Google Scholar 

  33. Fareed, J., Jeske, W., Hoppensteadt, D., Clarizio, R., and Walenga, J. M. (1998) Low-molecular-weight heparins: pharmacological profile and product differentiation. Am. J. Cardiol. 82, 3L–10L.

    Article  PubMed  CAS  Google Scholar 

  34. Boneu, B., Caranobe, C, Cadroy, Y., Dol, F., Gabaig, A. M., Dupouy, D., et al. (1988) Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin. Thromb. Hemost. 14, 18–27.

    Article  PubMed  CAS  Google Scholar 

  35. Sutor, A. H., Massicotte, P., Leaker, M., Andrew, M. (1997) Heparin therapy in pediatric patients. Semin. Thromb. Hemost. 23, 303–319.

    Article  PubMed  CAS  Google Scholar 

  36. Fareedman, M. D. (1996) Low molecular weight heparins: an emerging new class of glycosaminoglycan antithrombotic. J. Clin. Pharmacol. 31, 298–306. Circulation 93, 2212–2245.

    Google Scholar 

  37. Fareed, J., Walenga, J. M., Hoppensteadt, D., Huan, X., and Nonn, R. (1989) Biochemical and pharmacological in-equivalence of low molecular weight heparins. Ann. NY Acad. Sci. 556, 333–353.

    Article  PubMed  CAS  Google Scholar 

  38. Lindahl, A. K., Abildgaard, U., and Stokke, G. (1990) Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb. Res. 59, 651–656.

    Article  PubMed  CAS  Google Scholar 

  39. Larnkjaer, A., Ostergaard, P. B., and Flodgaard, H. J. (1994) Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb. Res. 75, 185–194.

    Article  PubMed  CAS  Google Scholar 

  40. Ostergaard, P., Nordfang, O., Petersen, L. C., Valentin, S., and Kristensen, H. (1993) Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 23 (Suppl. 1), 107–111.

    PubMed  Google Scholar 

  41. Hull, R. D., Raskob, G E., Rosenbloom, D., Pineo, G., Lerner, R. G, Gafni, A., et al. (1997) Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. Arch. Intern. Med. 157, 289–294.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albany College of Pharmacy, Albany, NY

    Shaker A. Mousa

Authors
  1. Shaker A. Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Albany College of Pharmacy, Albany, NY

    Shaker A. Mousa

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc.

About this protocol

Cite this protocol

Mousa, S.A. (2004). Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases. In: Mousa, S.A. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods In Molecular Medicine™, vol 93. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-658-4:35

Download citation

  • DOI: https://doi.org/10.1385/1-59259-658-4:35

  • Publisher Name: Springer, Totowa, NJ

  • Print ISBN: 978-1-58829-083-0

  • Online ISBN: 978-1-59259-658-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation